Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | IDO1 | P14902 | 2/20 | 0.34 |
| ▸ | TDO2 | P48775 | 1/20 | 0.32 |
| ▸ | NOS3 | P29474 | 1/20 | 0.32 |
| ▸ | NOS1 | P29475 | 1/20 | 0.32 |
| ▸ | NOS2 | P35228 | 1/20 | 0.32 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25544861 | 0.91 | PGR (0.35) | KDM4EMAPTMEN1KMT2AIDO1 | |
| SCHEMBL25544841 | 0.88 | IDO1 (0.37) | KDM4EMAPTMEN1KMT2AIDO1 | |
| SCHEMBL25544996 | 0.86 | PGR (0.35) | KDM4EMAPTMEN1KMT2AIDO1 | |
| SCHEMBL25544847 | 0.85 | IDO1 (0.36) | KDM4EMAPTMEN1KMT2AIDO1 | |
| SCHEMBL25544856 | 0.84 | IDO1 (0.40) | KDM4EMAPTMEN1KMT2AIDO1 | |
| SCHEMBL548396 | 0.79 | IDO1 (0.45) | KDM4EMAPTMEN1KMT2AIDO1 | |
| SCHEMBL25544858 | 0.78 | PGR (0.42) | MAPTIDO1ALOX15SMN1; SMN2 | |
| SCHEMBL25544989 | 0.78 | PGR (0.42) | MAPTIDO1ALOX15SMN1; SMN2 | |
| SCHEMBL25544846 | 0.77 | APP (0.36) | — | |
| SCHEMBL23204962 | 0.76 | IMPDH2 (0.40) | KDM4EMAPTMEN1KMT2ACYP2A6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230301181-A1 | TERTIARY AMINE DERIVATIVE AND ORGANIC ELECTROLUMINESCENT DEVICE COMPRISING SAME | LAPTO CO., LTD. (KR) | 2023-09-21 | — | — | US | disclosed |
| EP-4183784-A1 | TERTIARY AMINE DERIVATIVE AND ORGANIC ELECTROLUMINESCENT DEVICE COMPRISING SAME | Lapto Co., Ltd. (KR) | 2023-05-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230301181-A1 | TERTIARY AMINE DERIVATIVE AND ORGANIC ELECTROLUMINESCENT DEVICE COMPRISING SAME | SAT1, FTO, SETDB1 | KDM4E 142/4885MAPT 745/4885MEN1 2032/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.